Recombinant interferon alfa-2b/Acyclovir/Lidocaine

干扰素α-2b/阿昔洛韦/利多卡因

Report date: 2026/02/14 13:58:44

Base Information

Drug NameRecombinant interferon alfa-2b/Acyclovir/Lidocaine
Drug Alias NameAcyclovir/Lidocaine/Recombinant interferon alfa-2bRecombinant interferon alfa-2b/Lidocaine/AcyclovirLidocaine/Acyclovir/Recombinant interferon alfa-2bHerpferonGerpferon
ClassificationBiologics > Protein drugs > Recombinant protein > Recombinant cytokines
Mechanisms of ActionInterferon alpha/beta receptor agonistsInnate antiviral immune response inducersDNA-directed DNA polymerase inhibitors
TargetsSodium channel alpha subunitInterferon alpha/beta receptorDNA-directed DNA polymerase
Therapy Area/IndicationsHerpesviridae InfectionsHerpes Genitalis
Global Approved IndicationsHerpesviridae InfectionsHerpes Genitalis
Approved Indications in ChinaN/A
Original Approved Country/TerritoryRussian Federation
Original Approved Date2009/03/01
Country/TerritoryRussian Federation
CombinationsYes AcyclovirLidocaineInterferon alfa-2b (Merck Sharp & Dohme)
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesFirn M Zao
China Registration ClassN/A

Develop Information

Active CompaniesFirn M Zao
Inactive CompaniesN/A
Active IndicationsHerpesviridae InfectionsHerpes Genitalis
Inactive IndicationsN/A

Other Information

ATC CodeL03AB
Related LinksN/A